|
Synonyms: ZRC3308-A7
Compound class:
Antibody
Comment: Masavibart (ZRC3308-A7) is a potent, humanised IgG1 monoclonal antibody (mAb) with anti-viral potential aganist SARS-CoV-2 [1]. It binds to an epitope on the receptor binding domain (RBD) of the virus' spike protein, and blocks the spike interaction with host ACE2. Masavibart is one component of an antibody cocktail (ZRC3308) alongside a second mAb, ZRC3308-B10. These 2 mAbs bind non-overlapping spike RBD epitopes. ZRC3308 cocktail is effective against infection by the B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and AY.1 variants in vitro. In vivo efficacy has been demonstrated in the Syrian hamster SARS-CoV-2 infection model.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 12234 | masavibart |
| Synonyms |
| ZRC3308-A7 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 1267 |
| Other databases | |
| CAS Registry No. | 2640223-84-1 (source: WHO INN record) |
| GtoPdb PubChem SID | 479821113 |
| Search PubMed clinical trials | masavibart |
| Search PubMed titles | masavibart |
| Search PubMed titles/abstracts | masavibart |
